BCYC News and Press, Bicycle Therapeutics plc From 03/28/23

2023-03-28 07:27:49 ET Bicycle Therapeutics ( NASDAQ: BCYC ) signed an agreement with Novartis ( NYSE: NVS ) to develop and commercialize Bicycle radio-conjugates (BRCs) for multiple oncology targets. Under the agreement, Bicycle will get $50M upfront and is eligib...

- Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology - Bicycle will receive a $50 million upfront payment as well as potential milestones and tiered commercial royalties Bicycle Therapeutics plc (NASDAQ...

Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q4 GAAP EPS of -$1.01 beats by $0.05 . Revenue of $3.19M (-15.4% Y/Y) misses by $0.56M . For further details see: Bicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56M

- Significant progress across pipeline including advancing BT8009, BT5528, and BT7480 in ongoing clinical trials - BT8009 granted Fast Track Designation by the U.S. Food and Drug Administration; completed Phase I results presented at ASCO GU Cancers Symposium - Cash position of ...

Announcing the early-stage dose escalation results from its ongoing Phase I/II trial for BT8009, Bicycle Therapeutics ( NASDAQ: BCYC ) said Tuesday that the cancer candidate is linked to a complete response in a patient with bladder cancer. BT8009 is a bicycle toxin conjugate (BTC) ta...

50% overall response rate (ORR) and 75% clinical benefit rate, including one complete response in urothelial cancer at the 5 mg/m 2 dose on an intent-to-treat (ITT) basis As of January 2023, median duration of response (mDOR) is estimated to be approximately 14 months among urothelial...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the SVB Securities Gl...

- Company to Host Conference Call on February 14 at 8:00 a.m. ET - Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today a...

Clinical-stage biotech Bicycle Therapeutics ( NASDAQ: BCYC ) jumped ~10% pre-market Wednesday after announcing that the FDA granted Fast Track Designation for its experimental bladder cancer therapy BT8009. Specifically, the FDA has issued the Fast Track Designation for BT8009 as ...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track ...